TABLE 2.

Depression Outcomes (ITT Sample Based on Last Observation Carried Forward [LOCF]

	Acamprosate (n = 12)	Placebo (n = 11)	Significance (Acamprosate vs Placebo)
HAM-D-17 at baseline, mean ± SD	15.6 ± 5.2	20.7 ± 5.8	P = 0.036* Mann-Whitney: U = 33.00, Z = −2.03, P = 0.042*
HAM-D-17 at end point, mean ± SD	10.0 ± 7.2	12.9 ± 9.8	t = −0.814, df = 21, P = 0.425
Change in HAM-D-17 score, mean ± SD	−5.6 ± 8.5	−7.8 ± 9.9	t = 0.579, df = 21, P = 0.566
Significance for change in HAM-D-17 score	t = 2.28, P = 0.043* Wilcoxon: Z = −2.05, P = 0.041*)	t = 2.62, P = 0.026* Wilcoxon: Z = − 2.14, P = 0.033*	NA
QIDS-SR at baseline, mean ± SD	10.7 ± 3.5	13.2 ± 3.7	t = −1.667, df = 21, P = 0.110
QIDS-SR at end point, mean ± SD	7.5 ± 5.1	9.4 ± 6.2	t = −0.788, df = 21, P = 0.439
Change in QIDS-SR, mean ± SD	−3.2 ± 5.0	−3.8 ± 5.2	t = 0.308, df = 21, P = 0.761
Significance for change in QIDS-SR score	t = 2.22, P = 0.049* Wilcoxon: Z = −2.05, P = 0.040*	t = 2.44, P = 0.035* Wilcoxon: Z = −2.11, P = 0.035*	NA
CGI-S at baseline, mean ± SD	3.3 ± 0.8	4.4 ± 0.7	t = −3.378, df = 21, P = 0.003* Mann Whitney: U = 23.00, Z = −2.83, P = 0.005*
CGI-S at end point, mean ± SD	2.6 ± 1.2	3.0 ± 1.6	t = −0.705, df = 18, P = 0.490
Change in CGI-S, mean ± SD	−0.75 ± 1.4	−1.4 ± 1.7	t = 0.945, df = 21, P = 0.355
Significance for change in CGI-S score	t = 1.92, P = 0.082 Wilcoxon: Z = −1.64, P = 0.101	t = 2.59, P = 0.027* Wilcoxon: Z = −2.04, P = 0.041*	NA
CGI-I at end point, mean ± SD	2.8 ± 1.2	2.9 ± 1.5	t = −0.279, df = 21, P = 0.482
Response rate	50%	36%	χ2 = 0.43, P = 0.68
Remission rate	42%	36%	χ2 = 0.07, P = 1.00
Completers	7	5	χ2 = 0.38, P = 0.68

^*Statistically significant (P < 0.05).